$110.50
0.380.35%
最終更新: Oct 2, 10:24 AM
$109.44
-0.68-0.62%
Benzinga
Benzinga
Benzinga
金曜日, 10 02
Benzinga
© 2026 Benzinga | All Rights Reserved
Kymera Therapeutics (KYMR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.72 | $-0.86 | $-0.78 | $-0.76 |
| Actual | $-0.62 | $-0.71 | $-0.97 | $-0.90 |
| Surprise | +13.9% | +17.4% | -24.4% | -18.4% |
| Revenue | ||||
| Estimate | $32.6M | $8.8M | $16.2M | $24.5M |
| Actual | $65.0M | $34.4M | $2.9M | $2.8M |
| Surprise | +99.6% | +291.1% | -82.3% | -88.7% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.25 | $-1.26 | $-1.39 | $-1.42 |
| Revenue | ||||
| Consensus | $3.7M | $4.3M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.62 | $-0.72 | 13.9 % |
| Q1 | Apr 30, 2026 | $-0.71 | $-0.86 | 17.4 % |
| Q4 | Feb 26, 2026 | $-0.97 | $-0.78 | -24.4 % |
| Q3 | Nov 4, 2025 | $-0.90 | $-0.76 | -18.4 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $65.00M | $32.56M | 99.6 % |
| Q1 | Apr 30, 2026 | $34.37M | $8.79M | 291.1 % |
| Q4 | Feb 26, 2026 | $2.87M | $16.25M | -82.3 % |
| Q3 | Nov 4, 2025 | $2.76M | $24.51M | -88.7 % |